Evotec SE
EVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001412558
No open-market purchases or sales by Evotec SE insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $9.07M in total; no superinvestor holds it.
Other share classesEVOTF
Q3 2023 vs. Q2 2023
How the institutions holding Evotec SE changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 20 | 24 | +4 |
| Shares | 1.38M | 1.22M | −162.2K (−11.8%) |
| Value | $15.4M | $12.0M | −$3.44M (−22.2%) |
New holders (5)
Institutions that held Evotec SE at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cetera Investment Advisers | 25,638 | $253.0K | 0.00% |
| Briaud Financial Planning, Inc | 2,160 | $21.0K | 0.02% |
| Clearstead Advisors, LLC | 150 | $1.48K | 0.00% |
| JPMorgan Chase & Co | 135 | $1.33K | 0.00% |
| Qube Research & Technologies Ltd | 10 | $99 | 0.00% |
Sold out (1)
Institutions that held Evotec SE at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Jane Street Group, LLC | 18,310 | $206.9K |